Cardiovascular Drugs Practice Questions

Q: Statins act on:

HMG CoA reductase. ***HMG CoA reductase*** - **HMG-CoA reductase inhibitors** (statins) are the most effective and widely used class of hypolipidemic agents [1, 2, 3]. - This enzyme is the **rate-limiting step** in cholesterol biosynthesis in the liver [1, 2, 3]. *HMG CoA synthetase* - HMG-CoA synthetase is involved in the synthesis of **HMG-CoA** from acetyl-CoA and acetoacetyl-CoA. - This enzyme precedes the HMG-CoA reductase step and is **not the primary target** for cholesterol-lowering drugs. *Squalene epoxidase* - Squalene epoxidase is an enzyme involved in the later stages of the **cholesterol synthesis pathway**, specifically in converting squalene to squalene epoxide. - While inhibition of this enzyme would reduce cholesterol synthesis, it is **not the main target** of current widely used hypolipidemic agents. *HMG CoA hydratase* - HMG-CoA hydratase (also known as HMG-CoA lyase) is involved in the breakdown of HMG-CoA into **acetyl-CoA and acetoacetate** in ketogenesis. - It is **not directly involved** in the main pathway of cholesterol synthesis that is targeted by current hypolipidemic drugs.

Q: Which of the following vitamins can be used in high doses to treat hypercholesterolemia?

Niacin. ***Niacin*** - **Niacin** (Vitamin B3) in pharmacological doses effectively lowers **LDL cholesterol** and triglycerides while raising **HDL cholesterol**. - Its mechanism involves inhibiting **hepatic VLDL secretion** and decreasing the catabolism of **HDL**. *Vitamin B2* - **Vitamin B2** (riboflavin) is crucial for **cellular energy production** and acts as a cofactor in various enzyme reactions. - It does not have a significant role in **lipid metabolism** or in treating **hypercholesterolemia** at high doses. *Vitamin B5* - **Vitamin B5** (pantothenic acid) is a component of **coenzyme A**, essential for **fatty acid synthesis** and breakdown. - While involved in metabolism, it is not used therapeutically to manage **hypercholesterolemia**. *Vitamin B1* - **Vitamin B1** (thiamine) is vital for **carbohydrate metabolism** and **nerve function**. - There is no evidence supporting its use in treating **hypercholesterolemia**.

Q: Dobutamine mainly acts on which receptor:

Beta 1. ***Beta 1*** - **Dobutamine** is a direct-acting **beta-1 adrenergic agonist**, which means it primarily stimulates beta-1 receptors. - Stimulation of **beta-1 receptors** in the heart leads to increased **cardiac contractility** (positive inotropy) and heart rate (positive chronotropy), making it useful in conditions like **heart failure**. *Beta 2* - **Beta-2 receptors** are primarily found in the lungs and **vascular smooth muscle**. - Stimulation of **beta-2 receptors** causes **bronchodilation** and **vasodilation**, effects that are not the primary therapeutic goal of dobutamine. *Alpha 1* - **Alpha-1 receptors** are mainly located in **vascular smooth muscle** and cause **vasoconstriction** when stimulated. - While dobutamine may have some weak effects on alpha-1 receptors at higher doses, its dominant action is on beta-1 receptors, and significant vasoconstriction is not its primary clinical effect. *Alpha 2* - **Alpha-2 receptors** are largely presynaptic and act to inhibit the release of **norepinephrine**. - **Dobutamine** has minimal to no significant activity at **alpha-2 receptors**.

Q: All of the following are centrally acting antihypertensive drugs except:

Trimethoprim. ***Trimethoprim*** - **Trimethoprim** is an **antibiotic** and is not used as an antihypertensive drug. - It works by inhibiting **dihydrofolate reductase**, an enzyme involved in bacterial folate synthesis. *Methyldopa* - **Methyldopa** is a **centrally acting alpha-2 adrenergic agonist** that reduces sympathetic outflow from the central nervous system. - It decreases peripheral vascular resistance and heart rate, leading to a reduction in blood pressure. *Clonidine* - **Clonidine** is a **centrally acting alpha-2 adrenergic agonist** that stimulates alpha-2 receptors in the brainstem. - This stimulation reduces sympathetic outflow, leading to vasodilation and decreased heart rate. *Guanabenz* - **Guanabenz** is also a **centrally acting alpha-2 adrenergic agonist**. - It acts similarly to clonidine by stimulating central alpha-2 receptors to decrease sympathetic tone and lower blood pressure.

Q: Effects of beta blockers on the heart are all of the following except:

Decreases duration of systole. ***Decreases duration of systole*** - Beta-blockers primarily prolong the **duration of systole** by extending the **ejection time** and slowing ventricular relaxation. - They also increase the **diastolic filling time** by reducing heart rate, impacting overall cardiac cycle duration. *Decrease in heart rate* - Beta-blockers block **beta-1 adrenergic receptors** in the heart, leading to a decrease in **sympathetic stimulation** and thus a reduced heart rate. - This effect is beneficial in conditions like **tachycardia** and **angina**, as it reduces myocardial oxygen demand. *May decrease cardiac output initially.* - By reducing heart rate and contractility, beta-blockers can initially decrease **cardiac output**, especially in patients with pre-existing **ventricular dysfunction**. - This effect is often transient, as chronic use can lead to beneficial remodeling and improved efficiency in some conditions. *May precipitate heart failure in acute settings.* - In patients with acutely decompensated heart failure or severe left ventricular dysfunction, beta-blockers can acutely worsen cardiac function due to their **negative inotropic effects**. - Therefore, beta-blockers are typically initiated cautiously at low doses in stable heart failure patients and are contraindicated in acute decompensation.

Q: Most common digoxin-induced arrhythmia is

Ventricular Premature Beats. ***Ventricular Premature Beats (VPBs)*** - **Most common** digoxin-induced arrhythmia overall, occurring in up to 50-90% of digoxin toxicity cases. - Digoxin increases intracellular calcium through Na+/K+-ATPase inhibition, leading to **increased automaticity** and **delayed afterdepolarizations** that trigger ventricular ectopy. - **Hypokalemia** (common with concurrent diuretic use) significantly increases the risk by enhancing digoxin binding to Na+/K+-ATPase and further elevating intracellular calcium. - VPBs can manifest in various patterns including isolated beats, couplets, or organized patterns like ventricular bigeminy. *Ventricular bigeminy* - While ventricular bigeminy (every other beat is a VPB) is highly **characteristic** and specific for digoxin toxicity, it is a specific *pattern* of VPBs rather than the most common arrhythmia overall. - Represents severe ventricular irritability and indicates significant digoxin effect, but occurs less frequently than isolated VPBs. - When present, it strongly suggests digoxin toxicity and warrants immediate attention. *Ventricular Fibrillation* - A rare but **life-threatening** complication of severe digoxin toxicity. - Usually preceded by other ventricular arrhythmias (VPBs, ventricular tachycardia) and represents advanced toxicity. - Not common enough to be considered the "most common" digoxin-induced arrhythmia. *Atrial Flutter* - Digoxin can cause various atrial arrhythmias, but atrial flutter is relatively uncommon. - The most characteristic **atrial** arrhythmia in digoxin toxicity is **paroxysmal atrial tachycardia (PAT) with AV block**, not atrial flutter. - Digoxin's primary atrial effect is to slow AV nodal conduction, which may actually help control atrial flutter rather than cause it.

Q: Fish oil is not used in the treatment of:

Type 2A Hyperlipoproteinemia. ***Type 2A Hyperlipoproteinemia*** - **Fish oil** (omega-3 fatty acids) primarily lowers **triglyceride** levels. - In **Type 2A hyperlipoproteinemia**, the main lipid abnormality is elevated **LDL cholesterol**, with normal triglycerides, making fish oil less effective as a primary treatment. *Type 2B Hyperlipoproteinemia* - This condition involves elevated **LDL cholesterol** and moderately elevated **triglycerides**. - **Fish oil** can be beneficial in managing the elevated triglyceride component. *Type 5 Hyperlipoproteinemia* - Characterized by very high **triglyceride** levels and elevated **chylomicrons** and **VLDL**. - **Fish oil** is a key therapeutic agent for significantly reducing triglycerides in this severe form of hyperlipidemia. *Type 3 Hyperlipoproteinemia* - Also known as **familial dysbetalipoproteinemia**, this condition involves elevated **chylomicron remnants** and **VLDL remnants**. - **Fish oil** can help lower the triglyceride-rich lipoproteins seen in this disorder.

Q: HMG-CoA reductase is inhibited by:

Lovastatin. ***Lovastatin*** - **Lovastatin** is part of the statin class of drugs, which are potent competitive inhibitors of **HMG-CoA reductase**. - By inhibiting this enzyme, statins reduce the synthesis of **mevalonate**, a precursor to **cholesterol**, thereby lowering LDL-cholesterol levels. *Gemfibrozil* - **Gemfibrozil** is a **fibrate**, a class of drugs that primarily act by activating **peroxisome proliferator-activated receptor alpha (PPAR-α)**. - Its main effect is to decrease **triglyceride** levels and increase **HDL cholesterol**, not directly inhibit HMG-CoA reductase. *Clofibrate* - **Clofibrate** is also a **fibrate** and operates similarly to gemfibrozil by activating **PPAR-α**. - It primarily reduces **triglycerides** and has a modest effect on increasing HDL, but does not inhibit HMG-CoA reductase. *Nicotinic acid* - **Nicotinic acid** (niacin or vitamin B3) reduces hepatic synthesis of **VLDL** and inhibits the release of **fatty acids** from adipose tissue. - This leads to a decrease in **LDL cholesterol** and triglycerides, and an increase in **HDL cholesterol**, but it does not directly inhibit HMG-CoA reductase.

Q: Which drug is primarily known for inhibiting cardiac remodeling in congestive heart failure (CHF)?

ACE inhibitors. ***ACE inhibitors*** - **Angiotensin-converting enzyme (ACE) inhibitors** prevent the conversion of angiotensin I to angiotensin II, reducing detrimental effects like **vasoconstriction**, **aldosterone secretion**, and **cardiac hypertrophy**. - By inhibiting the **renin-angiotensin-aldosterone system (RAAS)**, ACE inhibitors effectively reduce cardiac preload and afterload, leading to the prevention or reversal of **cardiac remodeling**. *Digitalis* - Digitalis primarily acts as a **positive inotrope**, increasing the force of myocardial contraction, and slowing the heart rate, particularly in **atrial fibrillation**. - While it improves symptoms, it does not directly prevent or reverse **cardiac remodeling** and can have a narrow therapeutic index. *Diuretics* - Diuretics primarily reduce **fluid overload** and congestion in CHF by increasing **sodium and water excretion**, thereby decreasing preload. - They alleviate symptoms like **edema** and **dyspnea** but do not directly target or inhibit the underlying processes of **cardiac remodeling**. *Vasodilators* - Vasodilators (such as nitrates and hydralazine) reduce **cardiac preload** and/or **afterload**, improving symptomatic relief. - While they can improve hemodynamics, their primary action is not focused on preventing the cellular and structural changes associated with **cardiac remodeling**.

Q: ACE inhibitors, when used for a long time in hypertensive patients, cause

Reduction in filtration fraction. **Reduction in filtration fraction** - ACE inhibitors cause **vasodilation of the efferent arteriole** in the glomerulus. - This vasodilation leads to a **decrease in glomerular filtration pressure**, thereby reducing the filtration fraction. *Rightward shift in Renal pressure natriuresis curve* - A rightward shift in the renal pressure natriuresis curve indicates that a **higher blood pressure is required to excrete the same amount of sodium and water**. - ACE inhibitors typically cause a **leftward shift of this curve** by improving sodium and water excretion at lower pressures. *Significant increase in heart rate* - ACE inhibitors typically cause a **decrease or no significant change in heart rate**, as they interfere with the renin-angiotensin-aldosterone system (RAAS), which can affect sympathetic tone. - A significant increase in heart rate is **not a common or expected side effect** of long-term ACE inhibitor use. *No change in the compliance of large arteries* - Long-term use of ACE inhibitors can actually **improve arterial compliance** by remodeling the vessel walls and reducing stiffness. - This effect contributes to their **beneficial cardiovascular outcomes** beyond just blood pressure reduction.

Question 1

Statins act on:

Accepted Answer

HMG CoA reductase

Answer

HMG CoA synthetase

Answer

HMG CoA hydratase

Answer

Squalene epoxidase

Question 2

Which of the following vitamins can be used in high doses to treat hypercholesterolemia?

Accepted Answer

Niacin

Answer

Vitamin B2

Answer

Vitamin B5

Answer

Vitamin B1

Question 3

Dobutamine mainly acts on which receptor:

Accepted Answer

Beta 1

Answer

Beta 2

Answer

Alpha 1

Answer

Alpha 2

Question 4

All of the following are centrally acting antihypertensive drugs except:

Accepted Answer

Trimethoprim

Answer

Methyldopa

Answer

Clonidine

Answer

Guanabenz

Question 5

Effects of beta blockers on the heart are all of the following except:

Accepted Answer

Decreases duration of systole

Answer

Decrease in heart rate

Answer

May decrease cardiac output initially.

Answer

May precipitate heart failure in acute settings.

Question 6

Most common digoxin-induced arrhythmia is

Accepted Answer

Ventricular Premature Beats

Answer

Ventricular bigeminy

Answer

Atrial Flutter

Answer

Ventricular Fibrillation

Question 7

Fish oil is not used in the treatment of:

Accepted Answer

Type 2A Hyperlipoproteinemia

Answer

Type 2B Hyperlipoproteinemia

Answer

Type 5 Hyperlipoproteinemia

Answer

Type 3 Hyperlipoproteinemia

Question 8

HMG-CoA reductase is inhibited by:

Accepted Answer

Lovastatin

Answer

Gemfibrozil

Answer

Nicotinic acid

Answer

Clofibrate

Question 9

Which drug is primarily known for inhibiting cardiac remodeling in congestive heart failure (CHF)?

Accepted Answer

ACE inhibitors

Answer

Digitalis

Answer

Diuretics

Answer

Vasodilators

Question 10

ACE inhibitors, when used for a long time in hypertensive patients, cause

Accepted Answer

Reduction in filtration fraction

Answer

Rightward shift in Renal pressure natriuresis curve

Answer

Significant increase in heart rate

Answer

No change in the compliance of large arteries

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?